Antitumoral effects of growth hormone-releasing hormone (GHRH), in combination with chemotherapy for the treatment of malignant pleural mesothelioma.

Scientific research linked to the Mesothelioma Biology Bank

Use of new, broad spectrum analysis technologies to develop a detailed characterization of the molecular mechanisms

Multicenter biological and clinical observational study

PATIENT REPORTED OUTCOMES (PROs): EXPLORATORY EVALUATION OF PATIENTS WITH MESOTHELIOMA AND RARE TUMORS (PROsEXPLOR) IDEA/INNVOATION:

The identification of new and specific markers for Malignant Pleural Mesothelioma are of crucial importance for early diagnosis and treatment of MPM.

The purpose of this project is to validate and study the RON/MSP receptors implicated in malignant pleural mesothelioma.

The activation of beta estrogens has been investigated due to their involvement in the suppression of MPM pathogenesis, leading to potential therapies aimed at activating the estrogen receptor. 

Survivin is an excellent target for cancer immunotherapy because it is highly expressed in cancer cells but absent in normal tissue.

This research is being conducted at the laboratories of San Raffaele and the DISAV in conjuction with Professor Burlando. 

The purpose of this project is to find effective treatments for mesothelioma based on the genetic features of the patient’s cancer, avoiding the side effects usually experienced with chemotherapy. 

The purpose of this research is to evaluate drug resistance, taking a detailed look at the alterations of the tyrosine-kinase receptors which are often mutated in pleural mesothelioma.

Cancers, including MPM, contain tumor-initiating cells (TIC), which are a subpopulation of tumorigenic cells that are capable of self-renewal and differentiation and are also drug-resistant.